
Regeneron Pharmaceuticals’ Libtayo (cemiplimab) has been approved by the European Commission (EC) with an alternative, flexible dosing schedule across all approved skin, lung and cervical cancer indications.
The EC approval provides patients with the option to receive a higher, 700mg dose of Libtayo every six weeks infused intravenously over 30 minutes, after completing an initial 12 weeks of treatment with Libtayo 350mg infused intravenously over 30 minutes every three weeks.
Additionally, the approval allows those whose first 30-minute infusion of Libtayo 350mg was well tolerated to reduce their subsequent infusion times to 15- to 30-minutes at this dose level.
Libtayo is a prescription medicine used to treat adults with two types of skin cancer: cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC), along with adults with non-small cell lung cancer (NSCLC).
“Managing advanced cancer requires a significant investment of time and energy from patients, caregivers and clinical teams alike,” said Israel Lowy, Clinical Development Unit Head, Oncology, at Regeneron. “By offering an every-six-week maintenance schedule, and potentially halving infusion times for the every-three-week dose, we can help ease the burden of frequent clinic visits and longer infusion times for patients, while giving healthcare providers greater flexibility.”
The approval, which is supported by clinical safety and efficacy data from Libtayo’s clinical development programme, integrated with comprehensive pharmacokinetic (PK) and pharmacodynamic (PD) modelling and simulation data, applies across all six approved cancer indications for Libtayo in the European Union (EU):
A supplemental Biologics License Application (sBLA) for this alternative dosing regimen is under reviewIn the US, with a decision expected in March 2027.




